Systemic amyloidosis is a serious, rare disease caused by the buildup of abnormal protein deposits called amyloid in organs and tissues throughout the body. The abnormal proteins become insoluble amyloid fibrils that accumulate in tissues, interfering with their normal function. This deposition of amyloid fibrils in tissues can affect the functioning of major organs like heart, kidneys, liver and nerves. Currently, there is no cure for amyloidosis and available treatment options aim to reduce further amyloid formation, remove amyloid deposits from organs, and control symptoms. Chemotherapeutic and immunosuppressive drugs play a vital role in treatment and management of systemic amyloidosis.
The Global Systemic Amyloidosis Therapeutic Market is estimated to be valued at USD 6.19 Bn in 2024 and is expected to reach USD 10.99 Bn by 2031, growing at a compound annual growth rate (CAGR) of 7.9% from 2024 to 2031.
The rising prevalence of Systemic Amyloidosis Therapeutic Market and growing cases of misdiagnosis of amyloidosis disorders are fueling the demand for effective therapeutic options for treatment. Furthermore, rising awareness about amyloidosis is encouraging patients to seek timely diagnosis and treatment.
Get more insights on: Systemic Amyloidosis Therapeutic Market
Get this Report in Japanese Language: 全身性アミロイドーシス治療市場
Get this Report in Korean Language: 전신성 아밀로이드증 치료 시장
